Tricuspid Regurgitation Impact on Outcomes (TRIO): A Simple Clinical Risk Score

To determine which clinical variables infer the highest risk for mortality in patients with notable tricuspid regurgitation (TR) and to develop a clinical assessment tool (the Tricuspid Regurgitation Impact on Outcomes [TRIO] score). A single-center retrospective cohort of 13,608 patients with undif...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mayo Clinic proceedings 2022-08, Vol.97 (8), p.1449-1461
Hauptverfasser: Lara-Breitinger, Kyla M., Scott, Christopher G., Nkomo, Vuyisile T., Pellikka, Patricia A., Kane, Garvan C., Chaliki, Hari P., Shapiro, Brian P., Eleid, Mackram F., Alkhouli, Mohamad, Greason, Kevin L., Pislaru, Sorin V., Rihal, Charanjit S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To determine which clinical variables infer the highest risk for mortality in patients with notable tricuspid regurgitation (TR) and to develop a clinical assessment tool (the Tricuspid Regurgitation Impact on Outcomes [TRIO] score). A single-center retrospective cohort of 13,608 patients with undifferentiated moderate to severe TR at the time of index echocardiography between January 1, 2005, and December 31, 2016, was included. Baseline demographic and clinical data were obtained. Patients were randomly assigned to a training (N=10,205) and a validation (N=3403) cohort. Median follow-up was 6.5 years (interquartile range, 0.8 to 11.0 years). Variables associated with mortality were identified by Cox proportional hazards methods. A geographically distinct cohort of 7138 patients was used for further validation. The primary end point was all-cause mortality over 10 years. The 5-year probability of death was 53% for moderate TR, 63% for moderate-severe TR (hazard ratio [HR], 1.24 [95% CI, 1.17 to 1.31]; P
ISSN:0025-6196
1942-5546
1942-5546
DOI:10.1016/j.mayocp.2022.05.015